Table 1

Patient characteristics

NumberDiseaseAgeSexDMARDSteroidsDisease duration (months)C reactive protein (mg/l)ESR (mm/1st h)SF cellularity (109/ml)PDT
DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; SF, synovial fluid; PDT, population doubling time; RA, rheumatoid arthritis, SpA, spondyloarthropathy, IBD, inflammatory bowel disease; PsA, psoriatic arthritis; Juv, juvenile form; AS, ankylosing spondylitis; OA, osteoarthritis; uA, undifferentiated arthritis; MTX, methotrexate; SSZ, sulfasalazine; MP, methylprednisolone; MD missing data.
1RA70FemaleSSZ 2 g/dayNo881.559194.446
2RA59FemaleMTX 7.5 mg/weekNo422.4386.19.338
3RA36FemaleMTX 7.5 mg/week, SSZ 2 g/dayMP 4 mg/day4584916.49.7382
4RA51FemaleSSZ 2 g/dayNo818.1464.95.780
5RA62FemaleMTX 7.5 mg/weekNo420.9MDMD12.673
6RA67MaleNoNo17110.89520.66.67
7RA23FemaleNoMP 8 mg/day4380.38.3375
8RA52MaleMTX 15 mg/weekNo848.81333.312.5
9RA29FemaleNoNo24546111.58.671
10RA70FemaleMTX 10 mg/weekNo120445810.410.005
11RA52FemaleNoNo1.596.45312.58.9378
12SpA (IBD)30FemaleNoNo96MDMDMD6.67
13SpA (PsA)66MaleMTX 7.5 mg/weekNo86.8100.17.005
14SpA (Juv)21MaleSSZ 2 g/dayMP 4 mg/day4811711.87.337
15SpA (PsA)60FemaleMTX 15 mg/weekMP 4 mg/day2579257.6038
16SpA (PsA)33FemaleMTX 7.5 mg/week, SSZ 2 g/dayNo603.213MD8.671
17SpA (PsA)65FemaleMTX 15 mg/weekNo1206965MD9.338
18SpA (AS)41MaleNoNo19214176.59.338
19SpA (AS)48MaleSSZ 6 g/dayNo12434125.27
20OA60MaleNoNo31MDMDMD7.8706
21uA53MaleNoNoMD799.65.780
22uA29FemaleNoNo2MDMDMD5.336
23uA46FemaleNoNo6MDMD2.77.333
24uA64FemaleNoNo8297.97716.97